Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report.
Mustafa Zafer TemizAykut ÇolakerolIsmail UlusEnes KilicFilip PaslanmazSergen SahinEmrah YürükEngin KandiraliAtilla SemerciozAhmet Yaser MuslumanogluPublished in: Cancer immunology, immunotherapy : CII (2020)
Blood eosinophil count and percentage in patients with NMIBC can predict the disease recurrence during the BCG immunotherapy. Our research raised new questions and assumptions about the role of eosinophils during BCG immunotherapy.